Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen for activators or inhibitors of LAG-3 signaling in a cellular context and characterize the biological activity of LAG-3 and its interactions with ligands
Background: Lymphocyte-activation gene 3 (LAG-3, CD223) is a cell surface protein that belongs to immunoglobulin (Ig) superfamily. LAG-3 is expressed on activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its main ligand is MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. A number of LAG-3 antibodies are in preclinical development for treatments for cancer and autoimmune disorders. LAG-3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints are only activating effector T cells, and not inhibiting Treg activity where an antagonist LAG-3 antibody can both activate effector T cells (by downregulating the LAG-3 inhibiting signal) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human LAG-3 (lymphocyte-activation gene 3, CD223, GenBank Accession # NM_002286).
Format: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO
Host Cell Line: Jurkat
Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.
Storage Stability: Immediately upon receipt, store in liquid nitrogen.
Uniprot: P18627
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1